Tamer I. Khayal Sells 2,958 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,089,766.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

TransMedics Group Stock Down 3.4 %

Shares of NASDAQ TMDX opened at $138.97 on Friday. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The company has a fifty day moving average price of $156.02 and a 200 day moving average price of $133.71.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. During the same period in the prior year, the business earned ($0.03) EPS. The company’s revenue for the quarter was up 117.7% compared to the same quarter last year. As a group, equities analysts expect that TransMedics Group, Inc. will post 1.22 EPS for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently modified their holdings of TMDX. Hsbc Holdings PLC boosted its stake in shares of TransMedics Group by 19.0% during the 4th quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock worth $3,287,000 after buying an additional 6,650 shares during the last quarter. First Light Asset Management LLC boosted its stake in shares of TransMedics Group by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after buying an additional 136,217 shares during the last quarter. Osterweis Capital Management Inc. boosted its stake in shares of TransMedics Group by 78.5% during the 4th quarter. Osterweis Capital Management Inc. now owns 64,565 shares of the company’s stock worth $5,096,000 after buying an additional 28,390 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of TransMedics Group by 10.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after buying an additional 38,951 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after buying an additional 50,673 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on TMDX shares. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Robert W. Baird started coverage on shares of TransMedics Group in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 price objective for the company. Morgan Stanley upped their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Needham & Company LLC started coverage on shares of TransMedics Group in a research report on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective for the company. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $174.30.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.